No abstract available
Plain language summary
This Viewpoint discusses lecanemab use and the risk of cerebral macrohemorrhage for patients with mild cognitive impairment or early dementia.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Alzheimer Disease* / drug therapy
-
Alzheimer Disease* / epidemiology
-
Antibodies, Monoclonal, Humanized* / adverse effects
-
Antibodies, Monoclonal, Humanized* / therapeutic use
-
Cardiovascular Diseases* / epidemiology
-
Cardiovascular Diseases* / etiology
-
Cognitive Dysfunction* / complications
-
Cognitive Dysfunction* / drug therapy
-
Comorbidity
-
Humans
-
Uncertainty
Substances
-
Antibodies, Monoclonal, Humanized
-
lecanemab